Detailed Research: Economic Perspectives on TiVo, Eli Lilly, Rigel Pharmaceuticals, SpartanNash, Nustar GP, and Hornbeck Offshore Services — What Drives Growth in Today's Competitive Landscape

Loading...
Loading...

NEW YORK, Dec. 04, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of TiVo Corporation TIVO, Eli Lilly and Company LLY, Rigel Pharmaceuticals, Inc. RIGL, SpartanNash Company SPTN, Nustar GP Holdings, LLC NSH, and Hornbeck Offshore Services HOS, including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

TIVO DOWNLOAD: http://MarketSourceResearch.com/register/?so=TIVO
LLY DOWNLOAD:
http://MarketSourceResearch.com/register/?so=LLY
RIGL DOWNLOAD:
http://MarketSourceResearch.com/register/?so=RIGL
SPTN DOWNLOAD:
http://MarketSourceResearch.com/register/?so=SPTN
NSH DOWNLOAD:
http://MarketSourceResearch.com/register/?so=NSH
HOS DOWNLOAD:
http://MarketSourceResearch.com/register/?so=HOS

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Market Source Research, available for free download at the links above, examine TiVo Corporation TIVO, Eli Lilly and Company LLY, Rigel Pharmaceuticals, Inc. RIGL, SpartanNash Company SPTN, Nustar GP Holdings, LLC NSH, and Hornbeck Offshore Services HOS on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed November 30th, 2017. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

Loading...
Loading...

TiVo CORPORATION (TIVO) REPORT OVERVIEW

TiVo's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, TiVo reported revenue of $197.90MM vs $153.12MM (up 29.24%) and basic earnings per share -$0.14 vs $0.55. For the twelve months ended December 31st, 2016 vs December 31st, 2015, TiVo reported revenue of $649.09MM vs $526.27MM (up 23.34%) and basic earnings per share $0.35 vs -$0.05. TiVo is expected to report earnings on February 21st, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.36. The estimated EPS forecast for the next fiscal year is $1.75 and is expected to report on February 21st, 2018.

To read the full TiVo Corporation (TIVO) report, download it here: http://MarketSourceResearch.com/register/?so=TIVO

-----------------------------------------

ELI LILLY AND COMPANY (LLY) REPORT OVERVIEW

Eli Lilly's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Eli Lilly reported revenue of $5,658.00MM vs $5,191.70MM (up 8.98%) and basic earnings per share $0.53 vs $0.74 (down 28.38%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, Eli Lilly reported revenue of $21,222.10MM vs $19,958.70MM (up 6.33%) and basic earnings per share $2.59 vs $2.27 (up 14.10%). Eli Lilly is expected to report earnings on January 30th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.95. The estimated EPS forecast for the next fiscal year is $4.64 and is expected to report on January 30th, 2018.

To read the full Eli Lilly and Company (LLY) report, download it here: http://MarketSourceResearch.com/register/?so=LLY

-----------------------------------------

RIGEL PHARMACEUTICALS, INC. (RIGL) REPORT OVERVIEW

Rigel Pharmaceuticals' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Rigel Pharmaceuticals reported revenue of $0.90MM vs $3.76MM (down 76.06%) and basic earnings per share -$0.14 vs -$0.24. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Rigel Pharmaceuticals reported revenue of $20.38MM vs $28.90MM (down 29.46%) and basic earnings per share -$0.73 vs -$0.58. Rigel Pharmaceuticals is expected to report earnings on March 6th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.16. The estimated EPS forecast for the next fiscal year is -$0.49 and is expected to report on March 6th, 2018.

To read the full Rigel Pharmaceuticals, Inc. (RIGL) report, download it here: http://MarketSourceResearch.com/register/?so=RIGL

-----------------------------------------

SPARTANNASH COMPANY (SPTN) REPORT OVERVIEW

SpartanNash's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, SpartanNash reported revenue of $1,906.64MM vs $1,800.09MM (up 5.92%) and basic earnings per share -$3.32 vs $0.44. For the twelve months ended December 31st, 2016 vs December 31st, 2015, SpartanNash reported revenue of $7,734.60MM vs $7,651.97MM (up 1.08%) and basic earnings per share $1.52 vs $1.67 (down 8.98%). SpartanNash is expected to report earnings on February 28th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.53. The estimated EPS forecast for the next fiscal year is $2.21 and is expected to report on February 28th, 2018.

To read the full SpartanNash Company (SPTN) report, download it here: http://MarketSourceResearch.com/register/?so=SPTN

-----------------------------------------

NUSTAR GP HOLDINGS, LLC (NSH) REPORT OVERVIEW

Nustar GP's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Nustar GP reported revenue of $12.18MM vs $16.13MM (down 24.51%) and basic earnings per share $0.26 vs $0.40 (down 35.00%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, Nustar GP reported revenue of $56.10MM vs $79.67MM (down 29.59%) and basic earnings per share $1.28 vs $1.68 (down 23.81%). Nustar GP is expected to report earnings on January 30th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.14. The estimated EPS forecast for the next fiscal year is $1.34 and is expected to report on January 30th, 2018.

To read the full Nustar GP Holdings, LLC (NSH) report, download it here: http://MarketSourceResearch.com/register/?so=NSH

-----------------------------------------

HORNBECK OFFSHORE SERVICES (HOS) REPORT OVERVIEW

Hornbeck Offshore Services' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Hornbeck Offshore Services reported revenue of $53.67MM vs $51.93MM (up 3.35%) and basic earnings per share -$0.51 vs -$0.45. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Hornbeck Offshore Services reported revenue of $224.30MM vs $476.07MM (down 52.89%) and basic earnings per share -$1.76 vs $1.87. Hornbeck Offshore Services is expected to report earnings on February 21st, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.53. The estimated EPS forecast for the next fiscal year is -$2.72 and is expected to report on February 21st, 2018.

To read the full Hornbeck Offshore Services (HOS) report, download it here: http://MarketSourceResearch.com/register/?so=HOS

-----------------------------------------

ABOUT MARKET SOURCE RESEARCH

Market Source Research delivers the key research reports that help serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.

REGISTERED MEMBER STATUS

Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at compliance@MarketSourceResearch.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Hugo Moreau, Media Department
Office: +1 (704) 343-6361
E-mail: media@MarketSourceResearch.com

© 2017 Market Source Research. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@MarketSourceResearch.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Loading...
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsPress ReleasesAnalyst Recommendations
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...